Trial reportClinical lymphoma, myeloma & leukemia2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.
Trial report in Clinical lymphoma, myeloma & leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundProteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies form the backbone of initial treatment for myeloma and play an important role in the treatment of relapsed disease. However, global access to many novel therapies is limited and alkylating agents remain relevant in certain clinical settings. Ixazomib is an oral PI that enables development of all oral regimens. PATIENTS: We designed this open-label, multi-arm phase 2 study to evaluate the safety and efficacy of weekly oral ixazomib in various combinations for patients with relapsed MM. Herein, we discuss the results of Arms D (ixazomib, cyclophosphamide, and dexamethasone-ICd, n=33) and E (Daratumumab-ICd, n=24) that examined the ixazomib and dexamethasone in combination with cyclophosphamide or cyclophosphamide and daratumumab, respectively.
resultsThe overall response rate was 73% and 75% and ≥VGPR rate was 45% and 54% in the Arms D and E, respectively. After the median follow-up of 27 months for Arm D and 41 months for Arm E, the median progression free survival was 27.1 months (95% confidence interval [CI]: 17.8-38.6) and 37.7 months (95% CI: 17.9-NA) for the arms D and E, respectively. The median overall survival was not reached for either arm. A grade 3 or higher hematological adverse event considered at least possibly related, occurred in approximately 75% of patients.
conclusionsThe results of this phase 2 trial demonstrate clinically meaningful efficacy of ICd (±) daratumumab in the relapsed setting, with the indirect comparison suggesting a deeper response and longer PFS with adding daratumumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.